Project Grant K08HL177169
Award Date
12/1/24
Completion Date
11/30/29
Dollars Obligated
$143K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
This federal Project Grant award, valued at $708,266.00, was awarded on January 1, 2025 by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports research by The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to investigate the role of the long non-coding RNA SALTE1 in vascular aging and heart failure with preserved ejection fraction (HFPEF). The research...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,127,798 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for the period of February 1, 2025 to January 31, 2032. The grant supports a comprehensive research program to understand the role of macrophages in preserving cardiovascular health, illuminate their contributions to cardiovascular disease (CVD), and...
This $599,921 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research on the role of the RNA modification enzyme METTL3 in the cardiac benefits of exercise among individuals with diabetes. The awardee, The General Hospital Corporation (doing business as Massachusetts General Hospital), will conduct three specific aims to: 1) determine the role of METTL3 in the cardiac response to exercise in...
The National Heart, Lung, and Blood Institute (NHLBI) has awarded a $161,240 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The General Hospital Corporation (doing business as Massachusetts General Hospital) for a 5-year research project. The project aims to define the mechanisms by which endothelial sphingosine-1-phosphate receptor 1 (S1PR1) signaling promotes epithelial repair and regeneration in the lungs following viral-induced acute respiratory distress...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $190,491 to Beth Israel Deaconess Medical Center (Bidmc) from January 1, 2025 to December 31, 2029. The award supports research to characterize plasma protein markers associated with the blood pressure response during exercise and their relationship to the development of hypertension and cardiovascular disease. The...
This $171,450 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports a multi-omic investigation into the biological mechanisms linking excess body fat (adiposity) and elevated blood lipid levels as contributors to cardiovascular disease risk. The research, led by Dr. Dron at the Massachusetts General Hospital, aims to: (1) measure the interaction effects between adiposity and genetic factors on...
This R03 Project Grant for $125,250 was awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program. The grant funds a 2-year research project led by Dr. James Rhee at Massachusetts General Hospital (MGH) to study the role of the cytokine FAM3D in regulating cardiac fibrosis and inflammation in heart failure. The research aims to characterize how FAM3D affects cardiac fibroblasts and the lymphatic system, and evaluate its...
The National Heart, Lung, and Blood Institute (NHLBI) awarded Emory University a $127,645 Project Grant under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) to enhance the university's ability to train, mentor, and support new investigators in patient-oriented research on early cardiometabolic disease in children. The 5-year grant, awarded on August 15, 2024, will fund research aimed at understanding the physiological changes in children that lead to metabolic...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will provide $777,258 to Beth Israel Deaconess Medical Center, Inc. (Bidmc) to conduct research focused on improving the understanding of heart failure in patients with hypertrophic cardiomyopathy. The project aims to leverage advanced cardiac magnetic resonance imaging (CMR) techniques, including exercise CMR, to characterize the underlying...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $167,400 to Brigham & Women's Hospital Inc. to comprehensively investigate how the immune mediator CD70 regulates key endothelial and metabolic pathways related to vascular dysfunction and atherosclerotic cardiovascular disease. The award, effective March 1, 2025 through February 28, 2030, aims to elucidate: 1) CD70 regulation...